![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
|
Cryptocurrency News Articles
Dogecoin (DOGE) community celebrates “Dogeday” on April 20, awaiting upcoming deadlines for Dogecoin-related exchange-traded fund (ETF) applications.
Apr 20, 2025 at 05:47 pm
Dogeday marks the unofficial holiday of the Dogecoin (DOGE) community. It gained traction in the memecoin community four years ago, in 2021, during International Weed Day on April 20.
April 20 marks "Dogeday," an unofficial holiday celebrated by Dogecoin (DOGE) members worldwide.
The memecoin's community is also closely following upcoming deadlines for Dogecoin-related exchange-traded fund (ETF) applications.
Dogeday is an unofficial holiday within the Dogecoin community. It began in 2021 during International Weed Day on April 20.
The memecoin quickly gained traction among younger generations during the 2021 bull market, with many retail traders becoming interested in cryptocurrencies.
Despite its reputation as a joke token, Dogecoin remains the eighth-largest cryptocurrency by market capitalization, currently valued at $23.3 billion, according to CoinMarketCap.
Dogecoin's tokenomics have often been criticized for issuing 14.4 million worth of new DOGE into circulation per day, giving it a daily inflation rate of over $2.16 million.
"Dogecoin's staying power stems from a blend of community-driven enthusiasm, low entry barriers, and speculative appeal," said Anndy Lian, author and intergovernmental blockchain expert.
Dogecoin's inflationary tokenomics may also contribute to its retail appeal, Lian told Cointelegraph:
"The retail appeal is amplified by Dogecoin's meme-driven branding, which resonates with younger, internet-savvy investors."
Memecoins like Dogecoin lack underlying blockchain use cases and typically rally based on social media traction and retail hype alone.
In November 2024, Dogecoin's market capitalization surpassed that of Porsche, fueled by ongoing social media endorsements from billionaire Elon Musk.
Dogecoin community awaits DOGE ETFs deadline in May
The Dogecoin community is closely following the US Securities and Exchange Commission as it deliberates several DOGE-related ETF applications.
There are four Dogecoin ETF filings awaiting approval: the Bitwise Dogecoin ETF, the Grayscale Dogecoin ETF, the 21Shares Dogecoin ETF and the Osprey Fund Dogecoin ETF.
Grayscale's ETF application is due for a response on May 21 after the SEC delayed its decision on multiple crypto ETF filings.
Bitwise's filing could receive a response on May 18, which marks the end of the SEC's 75-day initial review period after the 19b-4 filing. However, the 240-day review period could enable the regulator to delay the decision until October 2024 for both filings.
The ETF applications from 21Shares and Osprey are still pending review for their initial 19b-4 filings, with no set deadline from the securities regulator.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
-
- Blurring the Lines Between Decentralized Finance and Traditional Finance, Ripple's XRP Ledger (XRPL) Is at the Center of a New Attempt to Integrate Blockchain into the Heart of Institutional Trading
- Apr 21, 2025 at 11:50 pm
- The lines between decentralized finance and traditional finance continue to blur now, Ripple's XRP Ledger (XRPL) is at the center of a new attempt to integrate blockchain into the heart of institutional trading.
-
-
-
- Novo Nordisk (NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019. Yet the stock has since plummeted 60% from its peak value.
- Apr 21, 2025 at 11:45 pm
- Despite strong growth and earnings momentum, the Danish biotech giant faces scrutiny over its positioning in the rapidly changing market for GLP-1 receptor agonists, as competition intensifies.
-
-
-